Adma Biologics (ADMA) Net Income towards Common Stockholders (2011 - 2026)

Adma Biologics (ADMA) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$133.3 million in Q4 2025.

• Quarterly Net Income towards Common Stockholders fell 367.26% year-over-year to -$133.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$35.7 million (down 126.34% YoY) and the FY2025 annual result came in at -$35.7 million, down 126.34% from the prior year.
• Net Income towards Common Stockholders slipped to -$133.3 million in Q4 2025, from $36.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $49.9 million in Q4 2024 to a low of -$133.3 million in Q4 2025.
• A 5-year average of -$1.4 million and a median of -$6.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders surged 1299.96% — and 2025, when it slumped 367.26%.
• Tracing ADMA's Net Income towards Common Stockholders over 5 years: stood at -$13.5 million in 2021, then climbed by 12.57% to -$11.8 million in 2022, then jumped by 189.84% to $10.6 million in 2023, then surged by 370.72% to $49.9 million in 2024, then slumped by 367.26% to -$133.3 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$133.3 million (Q4 2025), $36.4 million (Q3 2025), and $34.2 million (Q2 2025), per Business Quant data.